Revolutionary molecular imaging technologies detecting cancer at the cellular level before symptoms appear
The Canary Center at Stanford, established through the vision of Sanjiv Sam Gambhir, is a world leader in molecular imaging for early cancer detection. Research includes microbubble ultrasound, photoacoustic imaging, and PET scanning techniques.
Building on Dr. Gambhir's legacy, our imaging research combines physics, engineering, chemistry, and medicine to investigate technologies for early detection and visualization of molecular processes.
World-renowned expert in molecular imaging and founding director of the Canary Center, Dr. Gambhir revolutionized cancer detection through his pioneering work in PET scanning and molecular imaging technologies.
"We must detect cancer early enough to intervene and cure. Molecular imaging gives us eyes to see cancer at the cellular level, long before traditional methods can detect it."
Research using microbubble contrast agents to enhance ultrasound imaging and investigate pancreatic visualization.
Combines laser light and ultrasound to create detailed images of blood vessels and tissues, revealing tumor blood supply and molecular signatures.
Advanced PET scanning with novel radiotracers that target specific cancer molecules, enabling precise tumor identification and characterization.
Machine learning algorithms that analyze imaging data to identify subtle patterns invisible to the human eye, improving detection accuracy.
The cyclotron facility supports radiotracer production for molecular imaging research. This unique resource enables rapid development and testing of new imaging agents that can target specific cancer types and molecular pathways.
Evaluating microbubble contrast enhancement and quantitative ultrasound for pancreatic imaging.
Molecular breast imaging providing higher sensitivity than mammography for dense breast tissue and high-risk patients.
PSMA PET imaging enabling precise localization of prostate cancer for targeted biopsy and treatment planning.
Advanced imaging distinguishing benign from malignant lung nodules without invasive biopsy, reducing unnecessary procedures.
Help us continue Dr. Gambhir's legacy of developing revolutionary imaging technologies that save lives.